Why Some Urologists Consider Testosterone Therapy Beneficial in Men with Prostate Cancer
Testosterone therapy is no longer considered an absolute contraindication in carefully selected men who have undergone definitive treatment for prostate cancer, as contemporary evidence demonstrates it does not increase biochemical recurrence or disease progression, while significantly improving quality of life in symptomatic hypogonadal men. 1, 2, 3, 4
The Paradigm Shift in Understanding
The historical belief that testosterone "fuels" prostate cancer growth has been fundamentally challenged over the past two decades. This outdated concept was based on limited 1940s studies and anecdotal case reports 4. The key scientific breakthrough is the saturation model - which demonstrates that androgen receptors become saturated at relatively low testosterone levels (around 250 ng/dL), meaning additional testosterone beyond this threshold does not stimulate further prostate cancer growth 4.
Evidence Supporting Safety After Definitive Treatment
Post-Radical Prostatectomy
Men with favorable pathology (negative margins, negative seminal vesicles, negative lymph nodes) and undetectable PSA can be considered for testosterone therapy 5. A study of 103 hypogonadal men treated with testosterone after prostatectomy showed no increase in cancer recurrence rates, even in high-risk patients, though PSA levels did increase modestly 6. The recurrence rates were actually comparable or lower than untreated controls 2, 6.
Post-Radiation Therapy
Men treated with radiation therapy (with or without prior androgen deprivation) showed either steady PSA decline to <0.1 ng/mL or non-significant PSA changes when given testosterone therapy, without experiencing recurrence or progression 5.
Active Surveillance
Limited but emerging data suggest men on active surveillance do not experience significant PSA increases or subsequent cancer diagnosis compared to men not receiving testosterone 5.
Clinical Benefits That Drive Urologist Support
Urologists advocate for testosterone therapy in these men because hypogonadism severely impacts:
- Sexual function: Improved libido, erectile function, and overall sexual satisfaction 7, 8
- Physical health: Increased muscle mass, bone density, and reduced fat mass 7
- Mental health: Improved mood, energy, sense of well-being, and reduced depression 7
- Metabolic health: Better body composition and potentially improved insulin sensitivity 7
Importantly, severely hypogonadal testosterone levels may actually lead to worse oncological outcomes 3, creating a compelling argument for treatment.
Critical Monitoring Requirements
The 2018 Endocrine Society guidelines provide specific surveillance parameters 9:
Baseline Assessment:
- PSA and digital rectal examination before initiating therapy
- Exclude men with PSA >4 ng/mL or abnormal DRE findings
On-Treatment Monitoring:
- PSA at 3-12 months, then according to age-appropriate screening guidelines
- Urological consultation if:
- PSA increase >1.4 ng/mL within 12 months of starting therapy
- Confirmed PSA >4.0 ng/mL at any time
- New prostatic abnormality on DRE
- Substantial worsening of lower urinary tract symptoms
Hematologic Monitoring:
- Hematocrit at baseline, 3-6 months, then annually
- Intervention required if hematocrit >54% 9
Important Caveats and Contraindications
Absolute contraindications remain 7, 10:
- Active metastatic prostate cancer
- Locally advanced or metastatic disease (should only be considered in research settings) 5
Relative contraindications:
- Baseline hematocrit >48% (>50% at high altitude)
- Severe lower urinary tract symptoms
- Untreated obstructive sleep apnea
- Severe congestive heart failure 7
The Evidence-Practice Gap
Despite accumulating evidence, major guidelines still describe available data as inadequate, and many clinicians continue to decline testosterone therapy in any man with prostate cancer history 11. This conservative stance persists due to:
- Absence of large randomized controlled trials specifically in this population
- Medico-legal concerns
- Conservative interpretation of guideline language
- Limited training exposure 11
Practical Clinical Approach
For men with treated prostate cancer and symptomatic hypogonadism:
- Confirm hypogonadism with two morning testosterone measurements
- Verify cancer control: Undetectable or stable PSA, no evidence of recurrence
- Assess pathology: Favorable features preferred (negative margins, organ-confined disease)
- Shared decision-making: Discuss limited long-term data, need for intensive monitoring, and potential risks versus quality-of-life benefits
- Initiate therapy with any formulation (transdermal preferred for steady levels) 7
- Intensive surveillance: Follow the monitoring algorithm above rigorously
The key message: An absolute contraindication is no longer tenable in symptomatic hypogonadal men with definitively treated prostate cancer 11. The decision should be individualized based on cancer characteristics, treatment response, and patient preferences, but the option should be discussed rather than reflexively denied.